SAN FRANCISCO, Nov. 13 – Exelixis on Tuesday posted third-quarter revenues of $11.9 million versus $6.1 for the same quarter a year ago, the company announced.

The South San Francisco-based company attributed the revenue rise to new collaborations with Bristol-Myers Squibb and Protein Design Labs.

Exelixis reported a net loss of $13.4 million, or 28 cents per share for the third quarter of 2001, compared to a net loss of $5.5 million, or 13 cents per share for the third quarter of 2000. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.